University of California, Los Angeles.
Harvard Medical School, Boston, Massachusetts.
JAMA. 2022 May 24;327(20):1992-1997. doi: 10.1001/jama.2022.7013.
Glaucoma affects an estimated 2.7 million people in the US. It is the second-leading cause of irreversible blindness in the US and the leading cause of blindness in Black and Hispanic/Latino persons.
To update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for glaucoma in adults.
Adults 40 years or older who present in primary care and do not have signs or symptoms of open-angle glaucoma.
The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for glaucoma in adults. The benefits and harms of screening for glaucoma in adults are uncertain. More research is needed.
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma in adults. (I statement).
青光眼影响了美国约 270 万人。它是美国第二大致盲原因，也是黑人和西班牙裔/拉丁裔人群失明的主要原因。
为了更新其 2013 年的建议，美国预防服务工作组（USPSTF）委托进行了一项系统评价，以评估在成年人中筛查青光眼的益处和危害。
40 岁或以上在初级保健中就诊且没有开角型青光眼体征或症状的成年人。
USPSTF 得出的结论是，证据不足以评估在成年人中筛查青光眼的益处和危害之间的平衡。在成年人中筛查青光眼的益处和危害尚不确定。需要更多的研究。
USPSTF 得出的结论是，目前的证据不足以评估在成年人中筛查原发性开角型青光眼的益处和危害之间的平衡。（I 级声明）。
